NEUROD1 and type 2 diabetes mellitus: Interruption of the vicious cycle (Figure 8) triggered by the reduced phosphatase and the consequent ICER-mediated repression of NeuroD may be of clinical value in preventing β-cell failure and glucotoxicity in patients with Type 2 diabetes.